Oncodesign Precision Medicine (OPM) has announced positive results from its Phase 1 trial of OPM-101 in healthy volunteers, indicating the potential for treating diseases caused by deregulation of the RIPK2 kinase pathway. The company anticipates initiating a Phase 1b/2a clinical trial in late 2024 or early 2025. Additionally, OPM-201, licensed to Servier for Parkinson's disease, is nearing completion of its Phase 1 trial.
OPM-101 Phase 1 Results
The Phase 1 trial of OPM-101 demonstrated significant target engagement and an excellent safety profile. According to OPM, no treatment-related serious adverse events were observed, and no study discontinuations were required due to toxicity. The results suggest that OPM-101 meets and exceeds the serum levels required to inhibit RIPK2.
Philippe Genne, Chief Executive Officer of OPM, stated that the results are very positive and suggest great potential for this candidate, with no toxicity and an excellent pharmacological profile.
OPM-201 Progress
OPM-201, a first-in-class LRRK2 inhibitor for Parkinson's disease being developed by Servier, is also showing promising characteristics. The Phase 1 trial in healthy volunteers is nearing completion, and Servier is working towards launching its Phase 1b/2a trial.
Financial Highlights
OPM has secured €8.5 million in public funding for its research programs from innovation financing entities since January 1, 2024, with €1.9 million already received. The company's cash position stood at €9.6 million as of June 30, 2024. R&D investments totaled €3.6 million, including €2.9 million in proprietary programs, mainly for the clinical development of OPM-101 and preclinical screening in oncology.
Karine Lignel, COO of OPM, noted that the company raised almost 2 million euros on the markets, despite a very difficult stock market environment for biotechnologies and that the teams also worked hard to build up files and convince the key public players involved in financing innovation.
Preclinical Oncology Studies
Research teams have continued preclinical oncology studies for OPM-101 and its follower OPM-102, showing promising preclinical results. OPM and Navigo Proteins GmbH also signed a strategic collaboration agreement for the research and development of new agents for systemic radiotherapy under the COMETE (MRT) project.
About OPM
Oncodesign Precision Medicine (OPM) is a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers. OPM's pipeline includes kinase inhibitors targeting immuno-inflammatory diseases and oncology.
